|
|
| November 13, 2010: ROCKET-AF: Stroke Prevention Using the Oral Direct Factor Xa Inhibitor Rivaroxavan Compared with Warfarin in Patients wi |
Dr. Robert Califf, Dr. Manesh Patel, Dr. Ken Mahaffey and Dr. Keith Fox discuss: Stroke
Prevention Using the Oral Direct Factor Xa Inhibitor Rivaroxaban Compared with Warfarin in
Patients with Nonvalvular Atrial Fibrillation (ROCKET-AF) at AHA 2010
Kenneth W. Mahaffey, MD
Research Grants: AstraZeneca, Bayer, BI, BMS, Eli Lilly, J&J, Merck, Novartis,
Portola, Regado, Sanofi-Aventis, The Medicines Company
Consulting Fees: AstraZeneca, Bayer, BI, BMS, Eli Lilly, J&J, Merck, Novartis,
Sanofi-Aventis
No stock ownership
http://www.dcri.duke.edu/research/coi.jsp
Keith AA Fox, MB ChB
Research Grants: Bayer, Eli Lilly, J&J, Sanofi-Aventis
Consulting Fees: Bayer, Eli Lilly, J&J, Sanofi-Aventis
No stock ownership
[ Download video ] |
|
No comments have been submitted
|